Current concepts of pathogenesis and treatment of myasthenia gravis.
D000818:Animals; D000906:Antibodies / Q000032:analysis; D001327:Autoimmune Diseases; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003176:Complement C3 / Q000032:analysis; D046508:Culture Techniques; D000939:Epitopes; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D009045:Motor Endplate / Q000503:physiopathology*; D009132:Muscles; D009157:Myasthenia Gravis / Q000503:physiopathology / Q000628:therapy*; D009469:Neuromuscular Junction / Q000503:physiopathology*; D010956:Plasmapheresis; D051381:Rats; D011950:Receptors, Cholinergic; D012075:Remission, Spontaneous; D013934:Thymectomy; D013952:Thymus Hyperplasia / Q000150:complications
D000906:Antibodies; D002800:Cholinesterase Inhibitors; D003176:Complement C3; D000939:Epitopes; D007074:Immunoglobulin G; D011950:Receptors, Cholinergic